OR WAIT null SECS
Strengthens Operations to Support Global Clinical Trials with Wholly-Owned Lab in Europe
Rochester, NY, Mar. 9, 2009-ACM Global Central Laboratory announced today that it has acquired long-time partner lab, Pivotal Laboratories, based in York, UK, after working together under an exclusive alliance. The acquisition enables ACM Global Central Lab to further standardize and streamline operations for increased efficiencies.
Pivotal Laboratories, celebrating its 10th year of clinical laboratory testing, is recognized as an established force in the central laboratory market. It is dedicated solely to clinical trials central laboratory services serving the regions of Europe, Israel and South Africa, with a particular emphasis on growth within the countries of Central and Eastern Europe.
Jerry Boxall, Pivotal’s managing director said, “This is a very exciting development for us. Building on the success of our alliance over the past four years, this allows our unified group to continue its impressive record of growth. We are able to enhance our service offerings on a global basis while at the same time remaining true to our core values of flexibility, customer service and excellence in everything we do.”
“Our success and growth in the global market made this an economically viable business decision, and this was the next logical step in our relationship,” said Art Glenz, president and CEO, ACM Medical Laboratory. “The complete integration of the two companies places us in a stronger position, as we anticipate continued growth in the global clinical trials market.” The expanded operations will bring an increase in employment both in the U.S. and the UK.
“Establishing ownership in Europe strengthens our presence in this very important region” said Elena Logan, VP, Clinical Trials, ACM Global Central Lab. “A strategic acquisition such as this validates our global efforts.”
ACM Global Central Lab’s systems have always been seamlessly integrated and validated with the York lab, including a harmonized international database, reference ranges, uniform naming conventions and finance and administrative systems. The company is now able to centralize certain functional areas where cost savings are possible.
All of ACM Global Central Lab’s labs and regional partner labs are CAP-certified with fully standardized and validated systems. The company has worked with more than 6,000 sites in more than 1,500 protocols since 1997.
ACM Global Central Lab will be exhibiting at Partnerships with CROs in Orlando, Florida, April 28-30.
About ACM Global Central Lab
ACM Global Central Lab offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM’s operationsextend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 13 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.
For more information, visit www.acmgloballab.com.